Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo aims to improve leukemia treatment

NCT ID NCT06773936

First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 17 times

Summary

This study tests whether adding the drug asciminib to usual treatment works better for people newly diagnosed with a specific type of leukemia (Ph+ ALL). About 55 adults will receive a combination of asciminib, dasatinib, prednisone, and blinatumomab. The main goal is to see if this approach leads to a deeper remission of the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Baptist Memorial Health Care

    Memphis, Tennessee, 38120, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Northwell Health/Center for Advanced Medicine

    Lake Success, New York, 11042, United States

  • UC Irvine Medical Center

    Orange, California, 92868, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Cincinnati Cancer Ctr-UC Medical Ctr

    Cincinnati, Ohio, 45267, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.